Yiyang Lu1, Lihe Chen2, Binhong Zhao3, Zhou Xiao4, Ting Meng4, Qiaoling Zhou4, Wenzheng Zhang5. 1. Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China. Electronic address: luy6@mail.uc.edu. 2. Epithelial Systems Biology Laboratory, Systems Biology Center, NHLBI, Bethesda, MD 20892-1603, USA. 3. Department of Pathology and Laboratory medicine, The University of Texas, Medical School at Houston, 6431 Fannin Street, Houston, TX 77030. 4. Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China. 5. Albany Medical College, MC-165, 47 New Scotland Avenue, Albany, New York 12208. Electronic address: zhangw1@mail.amc.edu.
Abstract
AIMS: To investigate if urinary AQP5 serves as a new potential biomarker of diabetic nephropathy. METHODS: Using an AQP5-specific enzyme-linked immunosorbent assay, we measured serum and urine AQP5 first in a cohort consisting of normal controls (n=26) and patients with diabetes mellitus (n=25) or diabetic nephropathy (n=33) and then in a validation cohort possessing normal controls (n=10), patients with diabetes mellitus (n=10) or diabetic nephropathy (n=14), and patients with chronic kidney disease of unknown etiology (n=10). We used various statistical methods including Pearson's correlation coefficient, ANOVA with Holm-Sidak test, Receiver Operator Curve, and multiple logistic regression to analyze the data. RESULTS: Urine AQP5/creatinine 1) is significantly higher in diabetic nephropathy than in other two groups, and in diabetic nephropathy stage V than in stage III; 2) correlates with serum creatinine, urine albumin, and multiple other known risk factors of the disease; and 3) improves the clinical models in distinguishing diabetic nephropathy from normal controls and diabetic mellitus. CONCLUSION: Our data suggest that urine AQP5/creatinine may possess diagnostic and prognostic values as a biomarker of diabetic nephropathy.
AIMS: To investigate if urinary AQP5 serves as a new potential biomarker of diabetic nephropathy. METHODS: Using an AQP5-specific enzyme-linked immunosorbent assay, we measured serum and urine AQP5 first in a cohort consisting of normal controls (n=26) and patients with diabetes mellitus (n=25) or diabetic nephropathy (n=33) and then in a validation cohort possessing normal controls (n=10), patients with diabetes mellitus (n=10) or diabetic nephropathy (n=14), and patients with chronic kidney disease of unknown etiology (n=10). We used various statistical methods including Pearson's correlation coefficient, ANOVA with Holm-Sidak test, Receiver Operator Curve, and multiple logistic regression to analyze the data. RESULTS: Urine AQP5/creatinine 1) is significantly higher in diabetic nephropathy than in other two groups, and in diabetic nephropathy stage V than in stage III; 2) correlates with serum creatinine, urine albumin, and multiple other known risk factors of the disease; and 3) improves the clinical models in distinguishing diabetic nephropathy from normal controls and diabetic mellitus. CONCLUSION: Our data suggest that urine AQP5/creatinine may possess diagnostic and prognostic values as a biomarker of diabetic nephropathy.
Authors: Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: Bruce A Perkins; Linda H Ficociello; Bijan Roshan; James H Warram; Andrzej S Krolewski Journal: Kidney Int Date: 2010-01 Impact factor: 10.612
Authors: Mona A K Salem; Safinaz A el-Habashy; Omayma M Saeid; Mohamed M K el-Tawil; Perihan H Tawfik Journal: Pediatr Diabetes Date: 2002-03 Impact factor: 4.866
Authors: Nishant M Bhensdadia; Kelly J Hunt; Maria F Lopes-Virella; J Michael Tucker; Mohammad R Mataria; Joseph L Alge; Benjamin A Neely; Michael G Janech; John M Arthur Journal: Kidney Int Date: 2013-03-27 Impact factor: 10.612
Authors: Luigi Rossi; Maria Celeste Nicoletti; Monica Carmosino; Lisa Mastrofrancesco; Antonella Di Franco; Francesca Indrio; Rossella Lella; Luigi Laviola; Francesco Giorgino; Maria Svelto; Loreto Gesualdo; Giuseppe Procino Journal: J Diabetes Res Date: 2017-01-26 Impact factor: 4.011